Long on markets, short on patience. Interested in rom-coms, geopolitics, and money. Cofounder at Quicksilver Capital w/ @dylandoubledown and @loganteix | NFA
such a great story
Leopold Aschenbrenner just got the full “little kid steps up to the big table” experience.
Writes the AI manifesto, raises a couple hundred mil, runs it up to $20-45B with max leverage on memory/chips/power names + software shorts.
Up 439% through June. Feeling invincible.
Then July happens.
Positions get smoked 30-55%. Margin calls hit. Entire public book gets packaged and sold to Citadel in one trade.
He thought he was playing poker. The house just took the chips.
thanks for playing!
Here’s my first post:
LeBron James will be going to the sixers.
Current odds are ¢16 per contract on polymarket.
Get in while you can.
I’ll see you when it’s confirmed.
All time lows hitting on $SPCX, might be worth a peak. Still trading at insane multiples, but as Starship begins to make consistent trips, I expect SpaceX to rip.
Also, the lockup periods are confusing with $SPCX, but the logic is simple: no one is selling 6 months from now.
One thing worth thinking about when starting in corporate America:
Companies pay what it takes to hire and retain the people they need, not a dollar more. Every incremental dollar of comp comes straight out of earnings, and at a public company trading at 25x, that dollar costs shareholders $25 of market cap.
Your comp isn't a share of the profits. It's the market price of replacing you.
SEC's "request for comment" on ETF registration is basically telling everyone to launch whatever funds they want right now, as long as the exchanges are willing to list it.
Expect to see prediction market ETFs (Submersive), Active crypto, Anthropic ETFs, and many more.
No doubt that healthcare and biotechnology are going to make extreme advancements over the next 5-10 years. With the binary outcomes with most of this small companies, I feel like it is extremely complicated to find an edge. you are competing against PhDs who understand actual trial protocols and the FDA. I still think the best way to find names are through 13Fs by managers like EcoR1, and other high conviction managers.
Biology will deliver most of the returns in the stock market in the next two decades
The entire revolution hinges on our ability to read the proteome
Only one company can do that and no one is even close
$NAUT
And it's valued at just $200M
If AB 1383 keeps moving through the California Senate (which I think it will), it actually makes me more bullish on equities.
Why?
If CalPERS and other public pensions are forced to pay out more, their return targets become even harder to hit. That increases the incentive to move away from lower yielding assets (bonds) and toward higher return investments (stocks, private equity, hedge funds).
More liabilities often mean a greater search for return.
"The next wave of ETF innovation may not create the biggest opportunities for buyers, but rather create them for the shorts."
Learn about the trade leveraged ETFs are bringing us:
https://t.co/driYTnHDnr
Old chart. With 74% of the world's population connected to the internet, this still keeps me bullish on the AI buildout. More will adopt, more investment is needed, more value will be created.